The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Scarring of heart tissue can be slowed but not stopped, and can lead to heart failure. But a new study has shown that an ...

Niigata, Japan – Dr. Watanabe and his teams from Niigata University have revealed that PET/CT image analysis using artificial ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...

Background Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...